Key Highlights:
- Pfizer shares dropped 3% amid a wider market decline, despite positive European regulatory news.
- Analyst projections suggest a potential upside of over 25% from current levels.
- Pfizer's performance is projected to improve, with an "Outperform" rating from multiple brokerage firms.
Pfizer Inc. (PFE, Financial) encountered a challenging trading week, experiencing a 3% dip in share price. This decline, closely mirroring the broader market's 3.4% fall, largely results from investor unease over U.S. tariff policies. Despite these market headwinds, Pfizer marked significant progress by securing European approval for its RSV vaccine, ABRYSVO, targeted at younger adults, and striking a strategic partnership with Flagship Pioneering. Over the last year, Pfizer's total shareholder return, factoring in dividends, has decreased by 2.86%, falling short compared to the broader pharmaceuticals sector and the U.S. market performance.
Wall Street Analysts Forecast for Pfizer
According to projections from 19 analysts, the average price target for Pfizer Inc. (PFE, Financial) over the coming year is $30.86. Estimates range from a high of $41.43 to a low of $25.00. This average target implies a noteworthy upside potential of 25.59% from the current stock price of $24.58. Investors can explore more comprehensive estimate data on the Pfizer Inc. (PFE) Forecast page.
The consensus from 23 brokerage firms places Pfizer Inc. (PFE, Financial) at an average recommendation of 2.5, signaling an "Outperform" status. This recommendation is positioned within a rating scale that spans from 1 (Strong Buy) to 5 (Sell), indicating a positive outlook from analysts.
GuruFocus' analysis estimates the GF Value for Pfizer Inc. (PFE, Financial) at $28.65 in one year. This projection suggests a potential upside of 16.58% from the current trading price of $24.5761. The GF Value metric is derived from historical trading multiples, past business performance, and future growth forecasts, offering investors a benchmark for the stock's fair trading value. Detailed insights are available on the Pfizer Inc. (PFE) Summary page.
